Literature DB >> 16080421

Review and comparison of the long acting methylphenidate preparations.

Feng Liu1, Rafael Muniz, Haruka Minami, Raul R Silva.   

Abstract

The stimulants have been the mainstay of pharmacologic treatment for over fifty years. Methylphenidate is the most frequently prescribed of the stimulant agents. In the past, one of the main drawbacks of these agents was the abbreviated duration of action. Over the last few years three longer acting methylphenidate preparations have been released to the market. Though all these agents contain the same chemical compound they do vary in a number of ways. In this article we will present how the formulations compare in their technology and the differences in their delivery systems. We will also compare the available literature that focus on head to head comparisons in terms of pharmacokinetics studies and those reports that present efficacy data. Finally, we will suggest based on a theoretical framework on how to approach selecting an agent based on the results of these trials and the individual needs of the patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080421     DOI: 10.1007/s11126-005-2979-0

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  28 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

Review 3.  Attention-deficit hyperactivity disorder and hyperkinetic disorder.

Authors:  J M Swanson; J A Sergeant; E Taylor; E J Sonuga-Barke; P S Jensen; D P Cantwell
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

4.  Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

Authors:  R J Schachar; R Tannock; C Cunningham; P V Corkum
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-06       Impact factor: 8.829

5.  Methylphenidate bioavailability from two extended-release formulations.

Authors:  M A González; H S Pentikis; N Anderl; M F Benedict; H H DeCory; S J Hirshey Dirksen; S J Hatch
Journal:  Int J Clin Pharmacol Ther       Date:  2002-04       Impact factor: 1.366

6.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

Review 7.  Attention deficit disorder: a review of the past 10 years.

Authors:  D P Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-08       Impact factor: 8.829

8.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

9.  Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior.

Authors:  R L Sprague; E K Sleator
Journal:  Science       Date:  1977-12-23       Impact factor: 47.728

10.  Sustained release methylphenidate: pharmacokinetic studies in ADDH males.

Authors:  B Birmaher; L L Greenhill; T B Cooper; J Fried; B Maminski
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1989-09       Impact factor: 8.829

View more
  5 in total

1.  What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale.

Authors:  Anja Görtz-Dorten; Dieter Breuer; Christopher Hautmann; Aribert Rothenberger; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

2.  Methylphenidate modulates activity within cognitive neural networks of patients with post-stroke major depression: A placebo-controlled fMRI study.

Authors:  Rajamannar Ramasubbu; Bradley G Goodyear
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

3.  Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions.

Authors:  Fabian Haertling; Beate Mueller; Oliver Bilke-Hentsch
Journal:  Atten Defic Hyperact Disord       Date:  2014-10-28

4.  Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults.

Authors:  Xiaoxia Yang; John Duan; Jeffrey Fisher
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

5.  The effect of methylphenidate-OROS<sup>®</sup> on the narrative ability of children with attention-deficit hyperactivity disorder.

Authors:  Tessa L Rausch; Diane L Kendall; Sara T Kover; Elizabeth M Louw; Ursula L Zsilavecz; Anita Van der Merwe
Journal:  S Afr J Commun Disord       Date:  2017-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.